Co-Development and Production of Biologics, Vaccines, and Medicines.

About

We offer to integrate our productive and scientific-technological development capabilities into international consortia for the development and industrial scaling of innovative medical products. We have a consolidated ecosystem of public and private organizations, backed by a world-renowned regulatory agency, ready to co-develop, license, and produce vaccines, biologics, medicines, and diagnostic kits, especially for diseases of regional and global impact.

OUR APPROACH AND VALUE ADDED:

We possess a robust ecosystem of companies, public laboratories, and R&D centers with mature human and technological capabilities for the development and production of medicines, vaccines, biological products, and diagnostic reagents. This capacity, with roots in the mid-20th century, has demonstrated its resilience and competitiveness, supplying a large part of local and Latin American demand. A recent example is the capacity demonstrated during the pandemic to produce COVID-19 vaccines under license and, critically, to develop and manufacture a proprietary platform vaccine, in addition to various diagnostic kits.

This ecosystem is enhanced by dynamic scientific-technological systems seeking openness and the development of new ideas, and by the recent incorporation of advanced capabilities in nanotechnology and "on demand" production of low-turnover medicines, opening the door to personalized medicine. We have experience in developing solutions for both high-impact diseases (dengue, Chagas) and rare or neglected diseases, where "in house" developments of diagnostic kits often require industrial scaling. This entire process is accompanied by a national regulatory agency considered among the most specialized in the world, guaranteeing the highest quality standards.

EXPECTED RESULT AND NEED FOR COOPERATION:

The final result is the creation of more resilient, diversified, and need-close pharmaceutical supply chains, accelerating access to innovative health solutions. Our objective is to position ourselves as a strategic production and development hub for European consortia. To this end, we seek to integrate into projects that require:

• A partner with high-quality, scalable, and validated GMP (Good Manufacturing Practice) production capabilities for the manufacture of active ingredients or finished products.

• A partner for technology transfer, co-development, and licensing of productive platforms (e.g., protein subunit vaccines, mRNA) or specific products.

• Access to an agile and prestigious regulatory environment that facilitates approval processes and eventual product registration for regional markets.

• Opportunities for co-submission to international funding calls focused on pandemic preparedness, global health security, and decentralized pharmaceutical production, particularly in Horizon Europe Cluster 1 (Health) and Cluster 4 (Digital, Industry and Space) for advanced manufacturing aspects, and bilateral and region to region cooperation.

  PROFILE OF THE EUROPEAN CONSORTIUM SOUGHT:

  We seek to integrate into consortia led by European biopharmaceutical and biotech organizations, research centers, or public-private initiatives that possess technological platforms or innovative therapeutic candidates (vaccines, biologics, nanomedicines) in advanced preclinical or clinical development stages, and that require a strategic ally for large-scale manufacturing, joint development, or regional distribution. We especially value those partners interested in strengthening global health security, addressing neglected diseases, and establishing production chains closer to patients in Latin America, recognizing the strategic value of our industrial and regulatory capabilities.

  This integration represents a symbiotic opportunity: it provides European innovations with a high-quality manufacturing and commercialization route in a key region, while consolidating and projecting internationally the capabilities of the national scientific-productive complex, closing the cycle from research to industrial production. This opportunity naturally combines with the previous ones, as information generated in community diagnostics, clinical trials, and digital transformation can guide and validate the development of health solutions to be produced.